Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT02961764 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Bacterial Skin and Skin Structure Infections

Interventions

DRUG: Usual Care
DRUG: Dalbavancin

Sponsor

Allergan